Finger prick lab tests, Theranos

Following Study, Theranos Lab Tests Back in Question

By MedTech Intelligence Staff
Finger prick lab tests, Theranos

There are concerns over the accuracy of direct-to-consumer tests.

A study published yesterday by the Journal of Clinical Investigation (JCI) takes a look at clinical lab tests that are available to consumers via retail outlets. At issue is the question of whether these testing methods are technically accurate and provide clinical accuracy. And the results are once again casting a shadow over Theranos’ lab tests and how they could potentially alter clinical decisions.

In a study of 60 adults, the authors compared the uncertainty and accuracy of 22 common clinical lab tests performed by Theranos (finger-prick method), and Quest Diagnostics, Inc. and LabCorp. (traditional venipuncture). It found that Theranos flagged tests were outside the normal range 1.6 times more than the other testing services and that the Theranos sample collection had “higher sample rejection rates”.

“While laboratory practice standards exist to control this variability, the disparities between testing services we observed could potentially alter clinical interpretation and health care utilization,” the authors concluded. “Greater transparency and evaluation of testing technologies would increase their utility in personalized health management.”

The study, “Evaluation of direct-to-consumer low-volume lab tests in healthy adults,” is available on the JCI website.

Related Articles

About The Author

MedTech Intelligence